T0	LackOfOutcomeMeasurementData 15987 16073	did not call patients back for study visits for detailed assessment of quality of life
T1	LackOfOutcomeMeasurementData 16359 16429	we did not include delayed cerebral haemorrhage as a secondary outcome
T2	LackOfOutcomeMeasurementData 16452 16593	we did not include other baseline measurements such as amount of blood in CT scan or systemic illness, nor did we do close on-site monitoring
T3	LackOfOutcomeMeasurementData 16608 16679	we do not have complete information about adherence to study medication
T4	LackOfOutcomeMeasurementData 16681 16747	We did not require magnesium concentration to be routinely checked
T5	CareProvider 16830 16875	the possibility of unmasking of investigators
T6	ReliabilityOfMeasurement 17071 17204	effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed
T7	InappropriateFollowUpDuration 17371 17404	a benefit might be detected later
